ENTA
NASDAQ · Biotechnology
Enanta Pharmaceuticals Inc
$14.35
+0.46 (+3.31%)
Open$13.89
Previous Close$13.89
Day High$14.47
Day Low$13.76
52W High$17.15
52W Low$4.96
Volume—
Avg Volume177.0K
Market Cap446.32M
P/E Ratio—
EPS$-3.20
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+210.5% upside
Current
$14.35
$14.35
Target
$44.55
$44.55
$33.16
$44.55 avg
$53.28
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 95.23M | 104.45M | 75.01M |
| Net Income | -119,373,602 | -117,841,660 | -19,564,680 |
| Profit Margin | -125.4% | -119.1% | -26.1% |
| EBITDA | -117,731,402 | -122,677,231 | -21,379,947 |
| Free Cash Flow | — | — | -13,998,479 |
| Rev Growth | -8.8% | -8.8% | -3.9% |
| Debt/Equity | 2.21 | 2.21 | 0.40 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |